These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21344500)

  • 21. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
    Egan MF; Straub RE; Goldberg TE; Yakub I; Callicott JH; Hariri AR; Mattay VS; Bertolino A; Hyde TM; Shannon-Weickert C; Akil M; Crook J; Vakkalanka RK; Balkissoon R; Gibbs RA; Kleinman JE; Weinberger DR
    Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12604-9. PubMed ID: 15310849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia.
    Fujii Y; Shibata H; Kikuta R; Makino C; Tani A; Hirata N; Shibata A; Ninomiya H; Tashiro N; Fukumaki Y
    Psychiatr Genet; 2003 Jun; 13(2):71-6. PubMed ID: 12782962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of GRM3 polymorphism with white matter integrity in schizophrenia.
    Mounce J; Luo L; Caprihan A; Liu J; Perrone-Bizzozero NI; Calhoun VD
    Schizophr Res; 2014 May; 155(1-3):8-14. PubMed ID: 24680030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients.
    Liao DL; Hong CJ; Chen HM; Chen YE; Lee SM; Chang CY; Chen H; Tsai SJ
    Neuropsychobiology; 2003; 48(2):72-6. PubMed ID: 14504414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients.
    Yang Y; Li W; Zhao J; Zhang H; Song X; Xiao B; Yang G; Jiang C; Zhang D; Yue W; Lv L
    Behav Brain Funct; 2012 Feb; 8():11. PubMed ID: 22369141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.
    Stevenson JM; Reilly JL; Harris MS; Patel SR; Weiden PJ; Prasad KM; Badner JA; Nimgaonkar VL; Keshavan MS; Sweeney JA; Bishop JR
    Transl Psychiatry; 2016 Feb; 6(2):e739. PubMed ID: 26905411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of metabotropic glutamate receptor-3 variants on prefrontal brain activity in schizophrenia: An imaging genetics study using multi-channel near-infrared spectroscopy.
    Kinoshita A; Takizawa R; Koike S; Satomura Y; Kawasaki S; Kawakubo Y; Marumo K; Tochigi M; Sasaki T; Nishimura Y; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():14-21. PubMed ID: 25914064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia.
    Harrison PJ; Lyon L; Sartorius LJ; Burnet PW; Lane TA
    J Psychopharmacol; 2008 May; 22(3):308-22. PubMed ID: 18541626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.
    Sacchetti E; Magri C; Minelli A; Valsecchi P; Traversa M; Calza S; Vita A; Gennarelli M
    Pharmacogenomics J; 2017 Mar; 17(2):146-154. PubMed ID: 26856250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of serotonin-related gene polymorphisms on pathogenesis and treatment response in Korean schizophrenic patients.
    Kim YK; Yoon HK
    Behav Genet; 2011 Sep; 41(5):709-15. PubMed ID: 21399903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.
    Tsunoka T; Kishi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Okumura T; Inada T; Ozaki N; Iwata N
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):875-9. PubMed ID: 19386277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between symptom severity and well-being among Thai patients with schizophrenia: a cross-sectional analytical study.
    Teetharatkul T; Vitayanont A; Liabsuetrakul T; Aunjitsakul W
    BMC Psychiatry; 2021 Jul; 21(1):348. PubMed ID: 34253169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between genetic variants of the metabotropic glutamate receptor 3 (GRM3) and cognitive set shifting in healthy individuals.
    Baune BT; Suslow T; Beśte C; Birosova E; Domschke K; Sehlmeyer C; Konrad C
    Genes Brain Behav; 2010 Jul; 9(5):459-66. PubMed ID: 20132315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of metabotropic glutamate receptor 3 genotype on phonetic mismatch negativity.
    Kawakubo Y; Suga M; Tochigi M; Yumoto M; Itoh K; Sasaki T; Kano Y; Kasai K
    PLoS One; 2011; 6(10):e24929. PubMed ID: 22022368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.
    Smith RC; Chua JW; Lipetsker B; Bhattacharyya A
    J Clin Psychiatry; 1996 Oct; 57(10):460-6. PubMed ID: 8909332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study.
    Schwab SG; Plummer C; Albus M; Borrmann-Hassenbach M; Lerer B; Trixler M; Maier W; Wildenauer DB
    Psychiatr Genet; 2008 Feb; 18(1):25-30. PubMed ID: 18197082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GRM7 polymorphisms and risk of schizophrenia in Iranian population.
    Azari I; Moghadam RH; Fallah H; Noroozi R; Ghafouri-Fard S; Taheri M
    Metab Brain Dis; 2019 Jun; 34(3):847-852. PubMed ID: 30610437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia.
    Hong CJ; Yu YW; Lin CH; Cheng CY; Tsai SJ
    Psychiatr Genet; 2001 Dec; 11(4):219-22. PubMed ID: 11807413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.